Nutcracker Therapeutics Demonstrates Enhanced Functional Activity of Prostate Cancer Candidate NTX-470 at the 2024 AACR Annual Meeting
Retrieved on:
torsdag, april 11, 2024
Software, Research, Men, Pharmaceutical, Oncology, Consumer, Technology, Genetics, Clinical Trials, Science, Biotechnology, Health, PSMA, CD3, University, WT, STEAP1, RNA, Tumor microenvironment, Protein engineering, Prostate cancer, Engineering, HVEM, Patient, Cervical intraepithelial neoplasia, Toxicity, Messenger, Beauty, AACR, Therapy, Vaccine
Of these, NTX-470 showed the strongest target cell killing activity – it was capable of engaging CD3 T cells, while displaying minimal activity in the absence of STEAP1- or PSMA-expressing target cells, retaining low bystander activity.
Key Points:
- Of these, NTX-470 showed the strongest target cell killing activity – it was capable of engaging CD3 T cells, while displaying minimal activity in the absence of STEAP1- or PSMA-expressing target cells, retaining low bystander activity.
- LIGHT comes in two forms: membrane-bound or soluble, with the former generally having stronger activity, leading to the hypothesis that limiting membrane shedding would enhance advantageous activity.
- Nutcracker’s scientists engineered multiple variants of LIGHT with either flexible or rigid linkers in place of protease-sensitive sites, to explore how membrane shedding susceptibility affects immunomodulatory activity.
- Of the tested designs, membrane-stabilized variants of LIGHT enhanced HVEM stimulation over WT LIGHT and increased proinflammatory cytokines in the tumor microenvironment.